News
Despite the popularity of semaglutide drugs like Ozempic and Wegovy for weight loss, surveys suggest that most people still ...
You’ve likely heard the hype around Ozempic and Wegovy – weight loss drugs that have taken the world by storm. These ...
11h
HealthDay on MSNGLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, DepressionFor patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not ...
Glucagon-like peptide-1 receptor agonists are tied to a reduction in alcohol intake in patients being treated for obesity.
4d
HealthDay on MSNRisk of Obesity-Related Cancer Similar for GLP-1 Receptor Agonists and Bariatric SurgeryGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in ...
Data-driven clustering reveals distinct obesity phenotypes with unique clinical, behavioral, microbiome features, and differential GLP-1 responses.
5d
News-Medical.Net on MSNGLP-1 weight loss drugs leave users low on key nutrients, study findsThis study assessed nutrient intake in adults using GLP-1 receptor agonists (GLP-1RAs) and found widespread deficiencies in ...
News Evidence That GLP-1 Drugs Achieve Weight Loss Primarily by Reducing Fat Mass More Than Muscle. Diabetes and obesity have become pressing health issues worldwide. Glucagon-lik ...
GLP-1 receptor agonists are reshaping obesity care. OHE highlights access challenges, prescribing policy, and how patient and ...
GLP-1 RAs were associated with significant reductions in body weight, BMI, and waist circumference among pediatric patients with obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results